Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing
The proceeds will be used for research and development expenses primarily to advance its lead kt-3000 program toward human clinical trials
top of page
- May 26
- 6 min
AI/ML Innovations Inc. Announces Strategic Agreement with World Weight Loss, Inc.
Health Gauge Inc, is developing certain AI-powered powered products and services exclusively for World Weight Loss.
- May 2
- 6 min
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
“The Rakovina Therapeutics team is committed to developing new treatments that will improve outcomes for cancer patients,”
- Apr 21
- 5 min
AI/ML Innovations Introduces "Health Coach" - a Personalized AI-powered Health Advisor
Health Coach has functionality similar to ChatGPT, but is designed to monitor and manage the users health.
- Apr 21
- 5 min
Revive Therapeutics Provides Update of Phase 3 Clinical Study...
Revive will remain with the current protocol’s primary endpoint of proportion of patients meeting an endpoint of hospitalization or death..
- Apr 21
- 3 min
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
- Apr 21
- 1 min
Financial Post: Skylight Health Group
From an end-user point of view, Skylight represents a radical improvement in health care delivery..
- Apr 21
- 4 min
Rakovina Therapeutics Announces Preclinical Data Presentation...
Pre-clinical studies show potential synergy in treatment of solid tumors by combining a PARP inhibitor with inhibition of HDAC enzymes.
- Apr 21
- 4 min
Skylight Health Announces Strategic Investment from U.S. Institutional Healthcare Firm
The funds will be used to support Skylight on its pathway to profitability.
- Apr 21
- 4 min
Skylight Health to Participate in Medicaid Value-Based Care Model in Colorado
Skylight Health continues to see opportunities to expand value-based contracting efforts beyond traditional Medicare and Medicare Advantage.
- Apr 21
- 4 min
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
The Company is finalizing the Phase 3 study protocol of apabetalone in PCC and plans to launch the trial in the first half of 2023..
- Apr 21
- 1 min
Resverlogix will focus on the prevention and treatment of Post COVID-19 Conditions
The company’s new focus on patients with Post COVID-19 Conditions, known as long-COVID,
- Apr 21
- 4 min
Skylight Health Expands Value-Based-Care Plan in Florida
Skylight Health continues to see opportunities to expand current and engage with new provider partners for MA value-based care...
- Apr 21
- 1 min
Skylight Health Group NASDAQ:SLHG | TSXV:SLHG - a rapidly growing opportunity in value-based care
SLHG is focused on helping small and independent practices shift from a traditional fee-for-service model to value-based care...
- Apr 21
- 3 min
Skylight Health Provides Clinical Research Update
Research revenue in 2022 has more than doubled the $300,000 earned in 2021. The team continues to plan for further expansion to new markets.
- Apr 21
- 4 min
Resverlogix Publishes Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease..
“Apabetalone was associated not only with fewer negative cardiovascular outcomes, also relative improvements in liver fibrosis score"
- Apr 21
- 3 min
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
The lead optimization program being conducted in collaboration with the University of British Columbia is progressing as planned...
- Apr 21
- 4 min
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors.
- Apr 21
- 5 min
Rakovina Presents Preclinical Data at the 2022 AACR Special Conference on Sarcomas
Rakovina highlighted the development of its kt-3000 drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tutors..
- Apr 21
- 5 min
Resverlogix Announces Type C Meeting with FDA for Phase 3 High-risk COVID-19 Outpatient Study
FDA has granted the request for a meeting to review the clinical trial protocol for its Phase 3 study in high-risk COVID-19 outpatients.
1/17